Heron Therapeutics Stock Guidance | NASDAQ:HRTX

Comments

Heron Therapeutics Inc Stock Guidance

HRTXNASDAQ

Trade with Public

$0.8530

0.03364.10%

At close: Apr 10, 5:00 PM EST

$0.8530

N/A

After Hours: Apr 10, 4:00 PM EST

Overview News Earnings OptionsGuidanceAnalyst Ratings Insider Trades Short Interest Stock Report

Heron Therapeutics (HRTX) last issued guidance on February 26, 2026 for fiscal year 2026. The company guided revenue in the range of $173.00M - $183.00M for the period.

Compared to prior guidance, Heron Therapeutics raised its revenue forecast from a prior range of $40.50M - $40.50M.

Heron Therapeutics has issued 16 guidance updates between August 9, 2022 and February 26, 2026. During this period, the company raised its outlook 3 times and lowered it 5 times, providing investors with insight into management's evolving expectations.

Latest Guidance Date

Feb 26, 2026

Guidance Period

Full Year 2026

Revenue Guidance Range

$173.00M - $183.00M

Heron Therapeutics Guidance History

Review all historical guidance issued by Heron Therapeutics, including EPS and revenue forecasts across quarterly and annual periods.

Loading calendar...

FAQ

What is the most recent guidance for Heron Therapeutics (HRTX)?

The most recent guidance for Heron Therapeutics (HRTX) was reported on February 26, 2026 for the fiscal year 2026. Heron Therapeutics forecasted revenue between $173.00M and $183.00M for the period.

What revenue range did Heron Therapeutics (HRTX) guide for?

Heron Therapeutics (HRTX) guided revenue in the range of $173.00M to $183.00M for the fiscal year 2026.

Did Heron Therapeutics (HRTX) raise or lower guidance?

Heron Therapeutics (HRTX) raised its revenue guidance from a prior range of $40.50M - $40.50M to $173.00M - $183.00M for the fiscal year 2026.

When did Heron Therapeutics (HRTX) last issue guidance?

Heron Therapeutics (HRTX) last issued guidance on February 26, 2026 for the fiscal year 2026.

People Also Watch

Molecular Partners AG

NASDAQ:MOLN

$4.05

No data available

Kalaris Therapeutics Inc

Galectin Therapeutics Inc

Connect Biopharma Holdings Ltd

NASDAQ:CNTB

$2.88

2.28%

Burning Rock Biotech Ltd

NASDAQ:BNR

$17.48

10.32%

Fate Therapeutics Inc

NASDAQ:FATE

$1.22

-1.61%

Heron Therapeutics (HRTX) last issued guidance on February 26, 2026 for fiscal year 2026. The company guided revenue in the range of $173.00M - $183.00M for the period.

Compared to prior guidance, Heron Therapeutics raised its revenue forecast from a prior range of $40.50M - $40.50M.

Latest Guidance Date

Feb 26, 2026

Guidance Period

Full Year 2026

Revenue Guidance Range

$173.00M - $183.00M

Heron Therapeutics Guidance History

Review all historical guidance issued by Heron Therapeutics, including EPS and revenue forecasts across quarterly and annual periods.

											Get Alert
02/26/2026	HRTX	Heron Therapeutics	FY	2026	—	—	—	$173.00M	$183.00M	$171.84M	Get Alert
01/09/2026	HRTX	Heron Therapeutics	Q4	2025	—	—	—	$40.50M	$40.50M	$39.72M	Get Alert
01/09/2026	HRTX	Heron Therapeutics	FY	2025	—	—	—	$154.90M	$154.90M	$154.06M	Get Alert
11/04/2025	HRTX	Heron Therapeutics	FY	2025	—	—	—	$153.00M	$163.00M	$155.76M	Get Alert
08/08/2025	HRTX	Heron Therapeutics	FY	2025	—	—	—	$153.00M	$163.00M	$158.36M	Get Alert
05/06/2025	HRTX	Heron Therapeutics	FY	2025	—	—	—	$153.00M	$163.00M	$157.27M	Get Alert
02/27/2025	HRTX	Heron Therapeutics	FY	2025	—	—	—	$153.00M	$163.00M	$160.63M	Get Alert
11/12/2024	HRTX	Heron Therapeutics	Q4	2024	—	—	—	$37.00M	$43.00M	$40.73M	Get Alert
11/12/2024	HRTX	Heron Therapeutics	FY	2024	—	—	—	$140.00M	$146.00M	$148.40M	Get Alert
08/06/2024	HRTX	Heron Therapeutics	FY	2024	—	—	—	$138.00M	$158.00M	$147.85M	Get Alert
05/07/2024	HRTX	Heron Therapeutics	FY	2024	—	—	—	$138.00M	$158.00M	$144.87M	Get Alert
03/12/2024	HRTX	Heron Therapeutics	FY	2024	—	—	—	$138.00M	$158.00M	$139.10M	Get Alert
11/14/2023	HRTX	Heron Therapeutics	FY	2023	—	—	—	$123.00M	$125.00M	$124.61M	Get Alert
11/14/2023	HRTX	Heron Therapeutics	FY	2024	—	—	—	$138.00M	$158.00M	$156.57M	Get Alert
11/08/2022	HRTX	Heron Therapeutics	FY	2022	—	—	—	$93.00M	$95.00M	$107.14M	Get Alert
08/09/2022	HRTX	Heron Therapeutics	FY	2022	—	—	—	$93.00M	$95.00M	$106.69M	Get Alert

Loading calendar...

FAQ

What is the most recent guidance for Heron Therapeutics (HRTX)?

The most recent guidance for Heron Therapeutics (HRTX) was reported on February 26, 2026 for the fiscal year 2026. Heron Therapeutics forecasted revenue between $173.00M and $183.00M for the period.

What revenue range did Heron Therapeutics (HRTX) guide for?

Heron Therapeutics (HRTX) guided revenue in the range of $173.00M to $183.00M for the fiscal year 2026.

Did Heron Therapeutics (HRTX) raise or lower guidance?

Heron Therapeutics (HRTX) raised its revenue guidance from a prior range of $40.50M - $40.50M to $173.00M - $183.00M for the fiscal year 2026.

When did Heron Therapeutics (HRTX) last issue guidance?

Heron Therapeutics (HRTX) last issued guidance on February 26, 2026 for the fiscal year 2026.

People Also Watch

Molecular Partners AG

NASDAQ:MOLN

$4.05

No data available

Kalaris Therapeutics Inc

Galectin Therapeutics Inc

Connect Biopharma Holdings Ltd

NASDAQ:CNTB

$2.88

2.28%

Burning Rock Biotech Ltd

NASDAQ:BNR

$17.48

10.32%

Fate Therapeutics Inc

NASDAQ:FATE

$1.22

-1.61%

											Get Alert
02/26/2026	HRTX	Heron Therapeutics	FY	2026	—	—	—	$173.00M	$183.00M	$171.84M	Get Alert
01/09/2026	HRTX	Heron Therapeutics	Q4	2025	—	—	—	$40.50M	$40.50M	$39.72M	Get Alert
01/09/2026	HRTX	Heron Therapeutics	FY	2025	—	—	—	$154.90M	$154.90M	$154.06M	Get Alert
11/04/2025	HRTX	Heron Therapeutics	FY	2025	—	—	—	$153.00M	$163.00M	$155.76M	Get Alert
08/08/2025	HRTX	Heron Therapeutics	FY	2025	—	—	—	$153.00M	$163.00M	$158.36M	Get Alert
05/06/2025	HRTX	Heron Therapeutics	FY	2025	—	—	—	$153.00M	$163.00M	$157.27M	Get Alert
02/27/2025	HRTX	Heron Therapeutics	FY	2025	—	—	—	$153.00M	$163.00M	$160.63M	Get Alert
11/12/2024	HRTX	Heron Therapeutics	Q4	2024	—	—	—	$37.00M	$43.00M	$40.73M	Get Alert
11/12/2024	HRTX	Heron Therapeutics	FY	2024	—	—	—	$140.00M	$146.00M	$148.40M	Get Alert
08/06/2024	HRTX	Heron Therapeutics	FY	2024	—	—	—	$138.00M	$158.00M	$147.85M	Get Alert
05/07/2024	HRTX	Heron Therapeutics	FY	2024	—	—	—	$138.00M	$158.00M	$144.87M	Get Alert
03/12/2024	HRTX	Heron Therapeutics	FY	2024	—	—	—	$138.00M	$158.00M	$139.10M	Get Alert
11/14/2023	HRTX	Heron Therapeutics	FY	2023	—	—	—	$123.00M	$125.00M	$124.61M	Get Alert
11/14/2023	HRTX	Heron Therapeutics	FY	2024	—	—	—	$138.00M	$158.00M	$156.57M	Get Alert
11/08/2022	HRTX	Heron Therapeutics	FY	2022	—	—	—	$93.00M	$95.00M	$107.14M	Get Alert
08/09/2022	HRTX	Heron Therapeutics	FY	2022	—	—	—	$93.00M	$95.00M	$106.69M	Get Alert

Benzinga

Benzinga

Heron Therapeutics Inc Stock Guidance

Heron Therapeutics Guidance History

FAQ

What is the most recent guidance for Heron Therapeutics (HRTX)?

What revenue range did Heron Therapeutics (HRTX) guide for?

Did Heron Therapeutics (HRTX) raise or lower guidance?

When did Heron Therapeutics (HRTX) last issue guidance?

People Also Watch

Heron Therapeutics Guidance History

FAQ

What is the most recent guidance for Heron Therapeutics (HRTX)?

What revenue range did Heron Therapeutics (HRTX) guide for?

Did Heron Therapeutics (HRTX) raise or lower guidance?

When did Heron Therapeutics (HRTX) last issue guidance?

People Also Watch